therapi
chronic
hepat
c
chc
start
interferon
ifn
monotherapi
earli
therapi
consid
effect
case
present
standard
therapi
pegyl
ifn
ribavirin
achiev
sustain
virolog
respons
patient
howev
half
chc
patient
still
risk
fatal
liver
cirrhosi
hepatocellular
carcinoma
signific
event
hepat
c
viru
hcv
research
develop
cell
cultur
system
subgenom
replicon
system
enabl
robust
hcv
rna
replic
hepatoma
cell
recent
complet
life
cycl
hcv
achiev
use
genotyp
strain
hallmark
provid
much
inform
mechan
hcv
replic
includ
inform
host
molecul
requir
replic
antihcv
reagent
target
hcv
protein
develop
clinic
trial
howev
rnadepend
rna
polymeras
frequent
caus
mutat
hcv
genom
lead
emerg
drugresist
hcv
mutant
cellular
protein
essenti
hcv
rna
replic
alreadi
discov
use
hcv
cell
cultur
system
host
molecul
also
candid
target
antivir
describ
recent
progress
regard
antihcv
reagent
target
host
metabol
hepat
c
viru
hcv
discov
caus
agent
chronic
hepat
c
chc
liver
cirrhosi
hepatocellular
carcinoma
hcc
estim
million
peopl
worldwid
infect
hcv
ultim
goal
clinic
basic
hcv
studi
suppress
liverrel
death
caus
hcv
infect
respect
clinic
studi
interferon
ifn
play
major
role
treatment
patient
chc
ifn
therapi
start
ifn
monotherapi
earli
sustain
virolog
respons
svr
obtain
patient
ifn
therapi
develop
hepatologist
current
therapi
pegyl
ifn
pegifn
ribavirin
improv
svr
therefor
next
stage
therapi
chc
develop
new
antihcv
reagent
improv
svr
develop
ifn
therapi
strike
discoveri
basic
research
develop
cell
cultur
system
robust
hcv
rna
replic
lohmann
et
al
achiev
subgenom
hcv
rna
replic
human
hepatoma
cell
line
advantag
novel
system
known
replicon
system
provid
way
screen
antihcv
reagent
also
inform
mechan
hcv
rna
replic
cell
cultur
system
improv
recent
complet
life
cycl
hcv
achiev
use
genotyp
hcv
strain
newest
system
extend
target
antihcv
therapi
viru
infect
releas
effect
antihcv
reagent
select
cell
culturebas
screen
evalu
use
anim
model
system
hcv
infect
releas
clinic
trial
chimpanze
anim
model
earli
hcv
studi
howev
use
chimpanze
limit
ethic
financi
reason
addit
chimpanze
studi
use
tree
shrew
tupaia
belangeri
chinensi
report
differ
approach
studi
hcv
use
anim
model
achiev
use
relat
gb
viru
b
gbvb
gbvb
belong
flavivirida
famili
transmit
tamarin
marmoset
anim
model
may
valuabl
surrog
model
hcv
studi
anoth
approach
demonstr
studi
use
urokinas
plasminogen
activatorsever
combin
immunodefici
upascid
mice
transplant
human
hepatocyt
chimer
mous
model
support
chronic
hcv
viremia
circumst
without
immun
system
mass
screen
antihcv
reagent
use
cell
cultur
system
becom
power
tool
combin
small
anim
model
system
evalu
antivir
effect
select
reagent
clinic
trial
consid
new
strategi
chc
use
place
combin
ifn
main
target
hcv
protein
hcv
rna
respect
hcv
protein
two
nonstructur
ns
wellcharacter
proteas
rnadepend
rna
polymeras
rdrp
respect
sever
reagent
report
inhibitor
serin
proteas
includ
valopicitabin
report
inhibit
rdrp
hcv
rna
also
target
antivir
recent
rna
interfer
technolog
use
sirna
shrna
target
hcv
rna
rdrp
lack
proofread
activ
high
mutat
rate
rdrp
allow
viru
escap
reagent
target
hcv
protein
hcv
rna
antihcv
reagenttarget
viral
protein
genom
review
anoth
section
target
cellular
protein
essenti
hcv
rna
replic
infect
express
hcv
protein
thought
affect
host
cell
gene
express
profil
vise
versa
interact
specif
cellular
protein
hcv
protein
essenti
hcv
replic
tabl
cyclosporin
csa
one
best
character
inhibitor
target
cellular
protein
requir
hcv
replic
interact
cyclophilin
b
cypb
requir
hcv
rna
replic
csa
inhibit
hcv
rna
replic
interrupt
interact
cypb
heat
shock
protein
also
report
essenti
cellular
protein
hcv
rna
replic
knockdown
inhibit
shown
result
antihcv
activ
cell
cultur
upascid
mous
system
member
protein
famili
specif
interact
form
complex
la
autoantigen
la
polypyrimidin
tractbind
protein
ptb
also
candid
cellular
protein
inhibit
hcv
rna
replic
although
inhibitor
protein
report
date
thu
inhibit
metabol
recent
report
target
new
antivir
survey
recent
progress
enzym
inhibitor
cholesterol
sphingolipid
guanosin
triphosph
gtp
synthesi
pathway
well
metabol
pathway
hcv
discov
caus
agent
nona
nonb
hepat
chiron
corpor
howev
treatment
patient
nona
nonb
hepat
establish
discoveri
hcv
hoofnagl
et
al
report
treatment
normal
serum
alanin
aminotransferas
alt
level
patient
nona
nonb
hepat
sinc
initi
discoveri
antihcv
activ
becom
major
reagent
chc
treatment
replic
hcv
rna
seem
stimul
ifn
product
signal
recent
result
suggest
core
andor
induc
ifnstimul
gene
howev
viral
proteas
inhibit
ifn
product
although
complet
shut
therefor
exogen
ifn
administr
need
patient
chc
svr
affect
multipl
factor
genotyp
viral
load
durat
therapi
monotherapi
begun
earli
svr
achiev
patient
earli
ribavirin
combin
therapi
develop
svr
improv
furthermor
ifn
modifi
attach
peg
therebi
enhanc
stabil
blood
svr
current
standard
therapi
pegifn
ribavirin
high
current
pegifn
ribavirin
combin
therapi
genotyp
hcv
one
major
determin
svr
hcv
genotyp
classifi
group
genotyp
current
consid
problem
due
ifn
resist
exampl
genotyp
hcv
month
treatment
result
svr
patient
genotyp
month
treatment
achiev
svr
precis
mechan
ifn
resist
remain
unclear
howev
recent
develop
ifnresist
hcv
repliconharbor
cell
use
studi
examin
way
improv
svr
therefor
focu
treatment
patient
chc
shift
increas
svr
genotyp
hcv
develop
hcv
replicon
system
screen
antihcv
reagent
rather
difficult
hcv
replicon
system
develop
lohmann
et
al
first
mileston
hcv
studi
use
cell
cultur
system
replicon
system
provid
wealth
inform
concern
replic
machineri
hcv
make
strategi
achil
heel
hcv
base
inform
regard
hcv
rna
replic
hcv
replicon
improv
suitabl
system
screen
antihcv
reagent
introduct
report
gene
luciferas
howev
system
contain
structur
region
therefor
select
genomelength
hcv
rnarepl
cell
cultur
system
develop
second
mileston
infecti
viru
product
system
establish
three
group
use
genotyp
hcv
strain
system
extend
rang
hcv
studi
viral
entri
releas
therefor
life
cycl
hcv
cell
reconstruct
vitro
sinc
develop
hcv
replicon
infecti
hcv
product
system
mani
cellular
protein
identifi
essenti
host
molecul
hcv
rna
replic
hcv
replicon
report
lohmann
et
al
contain
neomycin
phosphotransferas
neo
encephalomyocard
viru
emcv
intern
ribosom
entri
site
ire
instead
hcv
structur
region
fig
hcv
replicon
consist
cistron
first
cistron
neo
translat
hcvire
second
cistron
translat
emcvir
introduc
region
upstream
ns
region
fig
develop
hcv
replicon
system
genomelength
hcv
rna
replic
system
use
differ
hcv
strain
h
n
develop
sever
group
genomelength
hcv
rna
replic
system
complet
open
read
frame
orf
hcv
introduc
second
cistron
instead
ns
region
fig
mass
screen
antihcv
reagent
evalu
level
hcv
rna
hcv
protein
requir
time
complic
procedur
facilit
monitor
replic
level
hcv
rna
report
gene
renilla
luciferas
fuse
neo
gene
system
antihcv
activ
evalu
valu
report
instead
pufa
quantif
hcv
rna
hcv
protein
shown
fig
contain
fuse
renilla
luciferas
neo
gene
first
cistron
one
clone
cell
line
establish
select
introduct
rna
cell
hcv
rna
hcv
protein
stabli
express
cell
renilla
luciferas
activ
correl
well
level
hcv
rna
therefor
antivir
effect
reagent
hcv
rna
replic
could
monitor
activ
renilla
luciferas
assay
system
facilit
mass
screen
antihcv
reagent
hcv
rna
replic
cell
contain
adapt
mutat
region
adapt
mutat
report
enhanc
replic
level
hcv
rna
cell
cultur
case
hcvo
two
adapt
mutat
requir
robust
replic
genomelength
hcv
rna
replic
exampl
authent
hcvo
rna
adapt
mutat
robustli
replic
cell
month
ikeda
et
al
unpublish
data
three
group
report
infecti
hcv
product
system
use
strain
cell
cultur
report
show
life
cycl
hcv
could
reconstruct
cell
thu
becam
landmark
search
ideal
hcv
cell
cultur
system
uniqu
featur
system
origin
strain
cell
line
genotyp
strain
deriv
patient
fulmin
hepat
requir
adapt
mutat
robust
replic
unlik
hcv
strain
uniqu
featur
system
employ
cell
huhlunet
cell
sinc
parent
cell
could
support
robust
product
infecti
hcv
recent
genotyp
strain
report
produc
infecti
hcv
cell
cultur
although
product
level
infecti
lower
compar
interestingli
five
adapt
mutat
introduc
genom
order
enhanc
effici
infecti
viru
product
presenc
adapt
mutat
strike
controversi
characterist
regard
product
infecti
hcv
describ
studi
need
understand
role
adapt
mutat
infecti
viru
product
establish
infecti
hcv
product
system
gradual
led
clarif
life
cycl
hcv
inform
regard
hcv
rna
replic
accumul
sinc
develop
hcv
replicon
system
infecti
hcv
product
system
provid
inform
step
viru
entri
releas
life
cycl
hcv
includ
receptor
bind
cell
entri
cytoplasm
releas
uncoat
iresmedi
translat
process
rna
replic
packag
assembl
virion
matur
virion
releas
although
mechan
still
unclear
step
target
antivir
among
protein
involv
step
proteas
step
polymeras
step
especi
well
character
specif
inhibitor
protein
develop
clinic
trial
patient
chc
cellular
protein
requir
hcv
rna
replic
may
determin
cell
tropism
hcv
hcv
parasit
util
cellular
protein
replic
machineri
therefor
cellular
protein
essenti
hcv
rna
replic
target
antivir
use
cell
cultur
system
sever
cellular
protein
identifi
effect
molecul
hcv
rna
replic
tabl
la
ptb
repres
molecul
report
essenti
host
factor
hcv
rna
replic
recent
immunosuppress
csa
report
inhibit
hcv
rna
replic
block
bind
cypb
protein
form
complex
geldanamycin
inhibitor
suppress
hcv
rna
replic
block
format
complex
advantag
inhibitor
target
cellular
factor
reagent
affect
viral
escap
achiev
mutat
high
mutat
rate
caus
rdrp
frequent
produc
escap
mutant
toward
antivir
reagent
hcv
protein
disadvantag
inhibitor
target
cellular
factor
may
induc
side
effect
inhibit
primari
role
cellular
factor
cellular
factor
target
antivir
independ
viral
escap
via
genet
mutat
caus
rdrp
cellular
factor
synthes
metabol
pathway
modifi
enzym
enzym
also
target
antivir
strategi
tabl
furthermor
reagent
alreadi
use
clinic
treatment
respect
diseas
one
advantag
use
exist
reagent
characterizationsinclud
safeti
side
effectshav
alreadi
perform
therefor
screen
exist
reagent
antihcv
new
field
antivir
develop
cell
cultur
system
hcv
led
revel
hcv
incorpor
mani
cellular
factor
replic
machineri
viru
inform
hcv
life
cycl
cell
cultur
assay
systemth
input
outputthat
need
develop
pool
antivir
reagent
discuss
particular
host
cell
metabol
pathway
current
target
antihcv
reagent
includ
recent
found
pitavastatin
ptv
fig
cholesterolbiosynthesi
pathway
region
downstream
mevalon
branch
separ
pathway
cholesterol
isoprenoid
synthesi
fig
attach
isoprenoid
call
prenyl
protein
prenyl
regul
varieti
cellular
function
growth
differenti
oncogenesi
farnesyl
pyrophosph
fpp
geranylgeranyl
pyrophosph
ggpp
mevalonatederiv
isoprenoid
attach
target
protein
farnesyltransferas
ftase
geranylgeranyl
transferas
type
ggtasei
respect
ftase
ggtasei
recogn
protein
substrat
ctermin
tetrapeptid
recognit
motif
call
caax
box
case
ggtasei
c
cystein
aliphat
amino
acid
x
leucin
isoleucin
valin
phenylalanin
product
mevalon
coenzym
hmgcoa
reductas
ratelimit
step
cholesterol
biosynthesi
statin
potent
hmgcoa
reductas
inhibitor
benefici
prevent
coronari
heart
diseas
statin
also
inhibit
prenyl
protein
lipid
metabol
essenti
life
cycl
mani
virus
cholesterolrich
lipid
raft
play
import
role
viru
entri
replic
assembl
hcv
also
form
replic
complex
lipid
raft
membran
structur
hcv
rna
replic
occur
lipid
raft
cholesterol
suppli
crucial
maintain
structur
lipid
raft
aizaki
et
al
report
lovastatin
lov
one
hmgcoa
reductas
inhibitor
inhibit
hcv
rna
replic
hcv
repliconharbor
cell
statin
also
possess
cholesterolindepend
action
pleiotrop
effect
mani
pleiotrop
effect
mediat
isoprenoid
exampl
inhibit
small
gtpbind
protein
ra
rho
whose
proper
membran
local
function
depend
prenyl
may
play
signific
role
pleiotrop
effect
statin
ra
rho
major
substrat
prenyl
fpp
ggpp
respect
gdpbound
ra
rho
local
cytoplasm
fpp
ggpp
bound
inact
ra
rho
transloc
cell
membran
convert
gtpbound
activ
form
recent
wang
et
al
identifi
one
geranylgeranyl
cellular
protein
requir
hcv
rna
replic
belong
fbl
famili
protein
contain
f
box
multipl
leucinerich
repeat
f
box
bind
multicompon
ubiquitin
ligas
complex
geranylgeranyl
bind
result
complex
seem
requir
hcv
rna
replic
hcv
repliconharbor
cell
knockdown
sirna
shown
reduc
hcv
rna
deplet
ggpp
statin
may
inhibit
geranylgeranyl
cellular
protein
caus
antihcv
effect
cell
statin
among
wide
use
reagent
lower
cholesterol
one
statin
use
clinic
lov
well
character
shown
antihcv
activ
cell
cultur
howev
antihcv
activ
statin
remain
clarifi
recent
antihcv
activ
sever
statin
character
use
assay
system
antihcv
activ
test
five
statin
atorvastatin
atv
fluvastatin
flv
pravastatin
prv
simvastatin
smv
lov
flv
exhibit
strongest
antihcv
activ
effect
concentr
inhibit
hcv
rna
replic
ec
atv
smv
show
moder
inhibitori
effect
ec
respect
howev
lov
report
inhibit
hcv
replic
shown
possess
weakest
antihcv
activ
ec
recent
found
ptv
possess
stronger
antihcv
activ
flv
fig
ec
ptv
calcul
antihcv
activ
statin
revers
suppli
mevalon
geranylgeraniol
howev
surprisingli
prv
exhibit
antihcv
activ
although
work
inhibitor
hmgcoa
reductas
although
prv
watersolubl
reagent
other
lipophil
prv
induc
express
hmgcoa
reductas
posit
feedback
mechan
may
anoth
mechan
underli
deplet
ggpp
statin
interestingli
report
prv
differ
effect
induct
compar
statin
ribavirin
reagent
current
use
treat
patient
chc
previou
studi
antihcv
activ
use
assay
system
ec
ribavirin
concentr
much
higher
clinic
achiev
ribavirin
concentr
report
previous
sinc
flvexhibit
strong
antihcvact
flv
examin
antihcv
activ
combin
ifn
cell
cotreat
flv
exhibit
synergist
inhibitori
effect
hcv
rna
replic
exampl
administ
combin
iu
ml
flv
level
hcv
rna
replic
remark
reduc
approxim
compar
effect
treatment
alon
combin
therapi
flv
may
effect
treatment
patient
chc
appropri
reduc
cholesterol
level
chc
patient
alreadi
normal
cholesterol
level
patient
statinrel
antihcv
reagent
possess
cholesterollow
activ
would
good
candid
futur
clinic
use
specif
inhibit
ggpp
synthesi
prenyl
worth
test
ggtasei
inhibitor
ggti
one
candid
purpos
furthermor
specif
inhibit
protein
modifi
ggtasei
may
effect
may
one
target
protein
format
complex
requir
hcv
rna
replic
therefor
reagent
block
associ
abl
inhibit
hcv
rna
replic
fewer
side
effect
prenyltransferas
recogn
broad
rang
protein
substrat
caax
motif
reid
et
al
report
list
hypothet
prenyltransferas
substrat
within
human
genom
host
molecul
involv
hcv
rna
replic
may
exist
list
antivir
activ
statin
also
report
virus
respiratori
syncyti
viru
rsv
lov
exhibit
antivir
activ
via
inhibit
rhoa
rhoa
activ
geranylgeranyl
activ
rhoa
interact
f
glycoprotein
rsv
flv
inhibit
cytomegaloviru
cmv
replic
abolish
cmvinduc
activ
involv
pathway
crucial
cmv
replic
human
immunodefici
viru
hiv
lov
siv
reduc
hiv
replic
via
suppress
bind
integrin
intercellular
adhes
molecul
lymphocyt
function
associ
statin
recent
shown
bind
virus
reduc
statin
dosedepend
manner
noteworthi
inhibit
bind
statin
independ
inhibit
hmg
coa
reductas
statin
inhibit
cholesterolbiosynthesi
pathway
branch
prenyl
pathway
deplet
mevalon
latter
caus
pleiotrop
effect
growth
differenti
antivir
howev
unknown
function
statin
may
existfor
exampl
bind
like
independ
cholesterollow
inhibit
prenyl
furthermor
find
prv
differ
effect
induct
statin
clearli
explain
character
mechan
statin
better
understand
find
may
lead
discoveri
statinrel
antihcv
reagent
exhibit
cholesterollow
activ
inhibit
prenyl
lipid
raft
deterg
resist
membran
drm
enrich
cholesterol
sphingolipid
activ
replic
complex
hcv
present
lipid
raft
therefor
sphingolipid
metabol
also
antivir
target
hcv
serin
palmitoyltransferas
spt
enzym
respons
condens
lserin
palmitoylcoa
produc
first
step
sphingolipid
biosynthesi
fig
myriocin
select
inhibitor
spt
inhibit
replic
hcv
replicon
sakamoto
et
al
report
compound
structur
similar
myriocin
also
inhibit
replic
hcv
replicon
identifi
secondari
fungal
metabolit
deriv
fusarium
sp
suppress
hcv
replicon
dosedepend
manner
ec
nm
examin
involv
sphingolipid
synthet
pathway
hcv
rna
replic
fumonisin
inhibitor
dihydroceramid
synthas
also
suppress
replic
hcv
replicon
mammalian
cell
ceramid
synthes
endoplasm
reticulum
er
transloc
golgi
compart
convers
sphingomyelin
inhibitor
ceramid
traffick
er
golgi
apparatu
also
inhibit
replic
hcv
replicon
glycosphingolipid
gsl
also
compon
lipid
raft
ppmp
inhibitor
gsl
biosynthesi
also
suppress
replic
hcv
replicon
furthermor
demonstr
treatment
ratio
drm
markedli
decreas
interestingli
howev
drm
fraction
affect
inhibit
sphingolipid
biosynthesi
disrupt
associ
lipid
raft
identifi
helixturnhelix
motif
sphingolipidbind
domain
sbd
similar
structur
sbd
loop
umehara
et
al
report
myriocin
suppress
hcv
rna
replic
vivo
use
hcvinfect
chimer
mice
human
liver
myriocin
reduc
hcv
rna
level
serum
liver
level
prior
day
treatment
also
demonstr
combin
treatment
myriocin
pegifn
reduc
hcv
rna
level
less
control
level
result
suggest
sphingolipid
biosynthet
pathway
also
suitabl
target
develop
hcv
therapi
begin
gtpbiosynthesi
pathway
inosin
monophosph
dehydrogenas
impdh
enzym
respons
convers
inosin
monophosph
imp
xanthosin
monophosph
xmp
fig
ribavirin
mizoribin
mycophenol
acid
mpa
impdh
inhibitor
inhibit
hcv
rna
replic
ribavirin
enhanc
svr
pegifn
therapi
compar
pegifn
monotherapi
howev
antivir
mechan
ribavirin
remain
clarifi
four
possibl
mechan
propos
direct
inhibit
rna
replic
inhibit
impdh
immunomodul
mutagenesi
ribavirin
phosphoryl
mono
di
triphosph
rmp
rdp
rtp
respect
rtp
analog
gtp
incorpor
replic
rna
rdrp
caus
termin
rna
synthesi
rmp
competit
inhibit
host
enzym
impdh
essenti
synthesi
gtp
caus
deplet
gtp
pool
rivavirin
suggest
caus
immunomodulatori
effect
shift
immun
respons
induc
hcvspecif
cell
respons
ribavirin
act
rna
mutagen
caus
error
catastroph
polioviru
replic
ribavirin
increas
mutat
rate
mutationsgenom
wild
type
mutationsgenom
result
decreas
infect
mutat
rate
increas
ribavirin
dosedepend
manner
mutationsgenom
mutationsgenom
respect
clinic
studi
chc
enhanc
svr
observ
combin
therapi
ribavirin
ifn
ribavirin
monotherapi
may
difficult
test
effect
ribavirin
monotherapi
sinc
clinic
achiev
concentr
ribavirin
without
sever
side
effect
anemia
low
howev
cell
cultur
model
higher
concentr
ribavirin
suppress
hcv
rna
replic
ec
mizoribin
imidazol
nucleosid
isol
cultur
medium
mold
eupenicillium
brefeldianum
structur
similar
ribavirin
mizoribin
author
japanes
govern
immunosuppress
drug
renal
transplant
thereaft
lupu
nephriti
rheumatoid
arthriti
nephrit
syndrom
also
ad
list
diseas
agent
indic
base
similar
mizoribin
ribavirin
antihcv
activ
mizoribin
test
use
assay
system
antihcv
activ
mizoribin
ec
similar
ribavirin
furthermor
low
dose
least
mizoribin
abl
enhanc
antivir
activ
ifn
mizoribin
report
exhibit
antivir
activ
influenza
viru
type
b
recent
bovin
viral
diarrhea
viru
sever
acut
respiratori
syndrom
sar
associ
coronaviru
precis
antivir
mechan
mizoribin
remain
unclear
howev
four
hypothes
mechan
ribavirin
mention
may
possibl
sinc
mizoribin
associ
sever
side
effect
altern
reagent
combin
therapi
ifn
like
mizoribin
mpa
use
immunosuppress
known
inhibit
impdh
report
show
vitro
antivir
activ
dengu
viru
hepat
b
viru
hbv
avian
reoviru
yellow
fever
viru
west
nile
viru
antihcv
activ
mpa
report
henri
et
al
clinic
relev
concentr
mpa
inhibit
hcv
rna
replic
approxim
studi
use
hcv
repliconharbor
cell
furthermor
combin
treatment
mpa
csa
ifn
show
synergist
inhibit
hcv
rna
replic
also
recent
confirm
combin
csa
mizoribin
synergist
effect
inhibit
hcv
rna
replic
yano
et
al
unpublish
data
data
suggest
immunosuppress
drug
possess
antihcv
activ
csa
mpa
mizoribin
may
prevent
reject
graft
also
recurr
hcv
infect
liver
transplant
combin
drug
may
addit
benefit
patient
revers
uncompetit
impdh
inhibitor
structur
unrel
known
impdh
inhibitor
markland
et
al
report
broadspectrum
antivir
activ
exhibit
potenc
ribavirin
hbv
human
cmv
rsv
herp
simplex
viru
type
parainfluenza
viru
emcv
venezuelan
equin
encephalomyel
viru
cell
cultur
zhou
et
al
report
alon
margin
effect
hcv
replicon
although
combin
treatment
ribavirin
enhanc
antihcv
activ
also
report
hcv
replicon
assay
system
mpa
show
margin
antihcv
effect
result
differ
antihcv
effect
mpa
report
henri
et
al
studi
need
clarifi
controversi
result
hcv
morphogenesi
target
antivir
life
cycl
viru
hcv
envelop
glycoprotein
highli
nglycosyl
consensu
sequenc
nglycosyl
asnxserthr
x
amino
acid
except
pro
contain
glycosyl
site
respect
previou
studi
use
bovin
viral
diarrhea
viru
inhibit
expect
prevent
proper
fold
assembl
hcv
therefor
nglycosyl
pathway
may
novel
molecular
target
antivir
chapel
et
al
report
antihcv
effect
inhibitor
bind
step
use
hcv
viruslik
particl
vlp
deriv
baculoviru
glucos
analogu
deoxynojirimycin
deriv
inhibitor
caus
retent
unprocess
hyperglycosyl
nlink
glycan
hcv
glycoprotein
led
reduct
bind
vlp
cell
result
examin
use
recent
develop
infecti
hcv
product
cell
cultur
system
inhibitor
may
one
candid
effect
combin
therapi
crucial
svr
patient
chc
receiv
current
standard
therapi
pegifn
plu
ribavirin
improv
current
valu
antihcv
effect
caus
jakstat
signal
pathway
duong
et
al
propos
hypomethyl
hcv
protein
caus
resist
ifn
therapi
unmethyl
less
activ
bound
inactiv
inhibitor
protein
inhibitor
activ
protein
arginin
methyltransferas
enzym
respons
methyl
hcv
protein
induc
express
catalyt
subunit
protein
phosphatas
overexpress
induc
hypomethyl
via
inhibit
final
interact
inhibit
hypomethyl
result
suppress
ifn
signal
sadenosyllmethionin
adomet
methyl
group
donor
methyl
adomet
use
treatment
alcohol
liver
diseas
avail
mani
countri
nonprescript
drug
betain
known
rais
intracellular
concentr
adomet
play
central
role
recycl
adomet
overexpress
uhvh
cell
signal
suppress
howev
cotreat
adomet
betain
restor
signal
result
suggest
addit
adomet
betain
current
standard
therapi
pegifn
ribavirin
may
enhanc
svr
patient
chc
lipid
metabol
one
import
pathway
hcv
rna
replic
cholesterol
sphingolipid
synthesi
fatti
acid
report
metabolit
involv
hcv
rna
replic
howev
precis
mechan
fatti
acid
hcv
rna
replic
remain
unclear
leu
et
al
report
polyunsatur
fatti
acid
pufa
inhibit
hcv
replicon
replic
arachidon
acid
aa
docosahexaeno
acid
dha
eicosapentaeno
acid
epa
belong
pufa
fig
possess
antihcv
activ
ec
aa
howev
acid
acid
gla
linol
acid
reduc
hcv
rna
level
slightli
satur
fatti
acid
includ
oleic
acid
myrist
acid
palmit
acid
steric
acid
slightli
enhanc
hcv
rna
level
similar
result
also
report
kapadia
et
al
use
genomelength
hcv
rnarepl
cell
line
aa
produc
lipid
mediat
prostaglandin
pg
thromboxan
tx
leukotrien
lt
lipoxin
lx
fig
howev
antivir
activ
eicosanoid
remain
unclear
clinic
studi
hyman
et
al
fig
fatti
acidbiosynthesi
pathway
pufa
metabol
diet
membran
phospholipid
report
oral
prostaglandin
therapi
result
benefici
effect
patient
chc
investig
antihcv
effect
metabolit
pufa
lead
new
field
antivir
base
host
metabol
ever
sinc
hcv
discov
caus
agent
nona
nonb
hepat
viru
ifn
play
central
role
treat
diseas
current
ifn
modifi
peg
accompani
power
partner
ribavirin
boost
antihcv
activ
ifn
develop
ifn
therapi
patient
chc
lack
robust
method
hcv
rna
replic
cell
cultur
hamper
research
hcv
life
cycl
discoveri
potent
new
antihcv
reagent
difficult
attack
achil
heel
hcv
without
inform
replic
machineri
viru
howev
develop
subgenom
replicon
system
lohmann
et
al
partial
reveal
hcv
life
cycl
inform
hcv
rna
replic
viru
life
cycl
provid
clue
develop
antivir
standpoint
viru
host
repres
exampl
discoveri
inhibit
innat
immun
hcv
run
cellular
first
defens
ifnproduct
system
serin
proteas
cleav
unexpect
cellular
target
cardif
disrupt
rigi
signal
hcv
replicon
contribut
discoveri
viral
serin
proteas
inhibitor
surprisingli
serin
proteas
inhibitor
inhibit
hcv
rna
replic
inhibit
activ
also
inhibit
rigi
signal
serin
proteas
inhibitor
possess
dual
function
inhibit
viral
cellular
cardif
protein
involv
ifn
product
viral
cellular
molecul
target
antivir
hcv
rdrp
caus
high
mutat
rate
mutat
accumul
viru
genom
high
mutat
rate
enhanc
viral
evolut
reagent
target
viral
protein
resist
therapi
happen
frequent
mutat
caus
rdrp
fact
clinic
trial
proteas
inhibitor
hcv
rna
rapidli
decreas
within
day
treatment
howev
hcv
rna
increas
around
day
treatment
hcv
mutant
may
problem
antihcv
reagent
cellular
protein
although
inhibit
primari
function
cellular
protein
may
caus
side
effect
review
host
metabol
pathway
overview
one
advantag
target
host
metabol
antivir
multipl
enzym
involv
metabol
could
becom
candid
antivir
strategi
target
host
metabol
care
regard
side
effect
caus
inhibit
primari
function
metabolit
minim
undesir
effect
pinpoint
inhibit
enzym
done
lipid
metabol
one
import
target
antivir
among
cellular
factor
recent
examin
effect
ordinari
nutrient
hcv
rna
replic
use
assay
system
found
linol
acid
possess
antihcv
effect
combin
csa
exert
synergist
inhibitori
effect
hcv
rna
replic
howev
antihcv
mechan
pufa
remain
unclear
improv
understand
antihcv
effect
pufa
extend
field
host
metabol
target
antivir
futur
one
recent
strike
advanc
develop
method
infecti
hcv
product
cell
cultur
system
provid
inform
regard
complet
life
cycl
hcv
extend
understand
antivir
viru
entri
assembl
releas
discoveri
antihcv
reagent
target
host
metabol
hcv
life
cycl
improv
svr
combin
ifn
develop
new
antihcv
reagent
could
lead
retir
ifn
near
futur
